{"entity":{"type":"insider","cik":"0001739920","url":"/insider/0001739920","json_url":"/insider/0001739920.json","name":"venBio Global Strategic Fund III, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":4,"n_filings":4,"first":"2021-07-01","last":"2024-07-22","span_basis":"filed_date"},"name_variants":[{"name":"venBio Global Strategic Fund III, L.P.","source":"filing","n_filings":4,"first_seen":"2021-07-01","last_seen":"2024-07-22"}],"transactions":[{"id":2579334,"accession":"0000905148-24-001964","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000905148-24-001964","line_url":"/filing/0000905148-24-001964#line-4","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; GOODMAN COREY S; VENBIO GLOBAL STRATEGIC GP III, L.P.; VENBIO GLOBAL STRATEGIC GP III, LTD; venBio Global Strategic Fund III, L.P.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":416666.0,"shares_display":"416,666","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":4999992.0,"total_display":"4,999,992.00","total_whole":"4,999,992","shares_owned_after":1936637.0,"shares_owned_after_display":"1,936,637","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-22","filed_date":"2024-07-22","scope":"insider"},{"id":6915566,"accession":"0001140361-22-021085","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-22-021085","line_url":"/filing/0001140361-22-021085#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Elevation Oncology, Inc.","issuer_ticker":"ELEV","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; GOODMAN COREY S; Royston Aaron; VENBIO GLOBAL STRATEGIC GP III, L.P.; venBio Global Strategic Fund III, L.P.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":702737.0,"shares_display":"702,737","price_per_share":4.1236,"price_display":"4.12","price_state":"stated","total_value":2897806.2932,"total_display":"2,897,806.29","total_whole":"2,897,806","shares_owned_after":1905430.0,"shares_owned_after_display":"1,905,430","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-25","filed_date":"2022-05-27","scope":"insider"},{"id":5471590,"accession":"0001567619-21-018677","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-21-018677","line_url":"/filing/0001567619-21-018677#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Ventyx Biosciences, Inc.","issuer_ticker":"VTYX","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"VENBIO GLOBAL STRATEGIC GP III, LTD; venBio Global Strategic Fund III, L.P.; VENBIO GLOBAL STRATEGIC GP III, L.P.; GOODMAN COREY S; Adelman Robert J","owner_display_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":312500.0,"shares_display":"312,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":3997269.0,"shares_owned_after_display":"3,997,269","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-25","filed_date":"2021-10-25","scope":"insider"},{"id":4187339,"accession":"0001567619-21-012858","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-21-012858","line_url":"/filing/0001567619-21-012858#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Elevation Oncology, Inc.","issuer_ticker":"ELEV","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic Fund III, L.P.; Royston Aaron; VENBIO GLOBAL STRATEGIC GP III, L.P.; Adelman Robert J; GOODMAN COREY S","owner_display_name":"venBio Global Strategic Fund III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":625000.0,"shares_display":"625,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":2608167.0,"shares_owned_after_display":"2,608,167","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-29","filed_date":"2021-07-01","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001817241","name":"Artiva Biotherapeutics, Inc.","url":"/issuer/0001817241","role":"Ten percent owner","n_filings":1,"first_seen":"2024-07-22","last_seen":"2024-07-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001783032","name":"Elevation Oncology, Inc.","url":"/issuer/0001783032","role":"Ten percent owner","n_filings":2,"first_seen":"2021-07-01","last_seen":"2022-05-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001851194","name":"Ventyx Biosciences, Inc.","url":"/issuer/0001851194","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-10-25","last_seen":"2021-10-25"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001739920","retrieved_at":"2026-08-23T10:13:39+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}